Windtree Therapeutics, Inc. (WINT) - Cash on Hand per Share

Windtree Therapeutics, Inc. - graphic logo of issuer WINT

Windtree Therapeutics (WINT) is attracting scientific interest with its cardiology developments, maintaining the image of a clinical venture project. The company aims to establish leadership in the treatment of acute heart failure through the implementation of innovative istaroxime. The cash per share figure demonstrates financial stability, with the metric holding around 0.00, confirming the diversification of the drug pipeline to mitigate FDA regulatory risks.

Windtree (WINT) - Cash per Share from 07/04/2022 to 09/06/2025

Comprehensive metric breakdowns and analytics for Windtree Therapeutics Inc. (WINT)

- market capitalization indicators:
- cash availability and cash flow indicators:
General company analysis:WINT, Windtree
Manufactured products of Windtree Therapeutics, Inc.

Windtree Therapeutics' development of cardiology drugs within the stable legal framework of the West is reflected in the current cash per share level. This indicator determines the portion of liquid reserves attributable to a single security. The calculation is based on dividing the total amount of cash by the number of shares outstanding. A high figure confirms the issuer's financial stability in the face of clinical risks. The humanitarian status of medicine minimizes external threats, transforming capital reserves into a tool for strategic development.